| Literature DB >> 32518204 |
Dongwon Choi1,2, Eunkyung Park1,2, Kyu Eui Kim1,2, Eunson Jung1,2, Young Jin Seong1,2, Luping Zhao1,2, Shrimika Madhavan1,2, George Daghlian1,2, Hansuh H Lee1,2, Patill T Daghlian1,2, Saren Daghlian1,2, Khoa Bui1,2, Chester J Koh3, Alex K Wong1, Il-Taeg Cho1,2, Young-Kwon Hong4,2.
Abstract
Kaposi sarcoma is the most common cancer in human immunodeficiency virus-positive individuals and is caused by Kaposi sarcoma-associated herpesvirus (KSHV). It is believed that a small number of latently infected Kaposi sarcoma tumor cells undergo spontaneous lytic reactivation to produce viral progeny for infection of new cells. Here, we use matched donor-derived human dermal blood and lymphatic endothelial cells (BEC and LEC, respectively) to show that KSHV-infected BECs progressively lose viral genome as they proliferate. In sharp contrast, KSHV-infected LECs predominantly entered lytic replication, underwent cell lysis, and released new virus. Continuous lytic cell lysis and de novo infection allowed LEC culture to remain infected for a prolonged time. Because of the strong propensity of LECs toward lytic replication, LECs maintained virus as a population, despite the death of individual host cells from lytic lysis. The master regulator of lymphatic development, Prox1, bound the promoter of the RTA gene to upregulate its expression and physically interacted with RTA protein to coregulate lytic genes. Thus, LECs may serve as a proficient viral reservoir that provides viral progeny for continuous de novo infection of tumor origin cells, and potentially BECs and mesenchymal stem cells, which give rise to Kaposi sarcoma tumors. Our study reveals drastically different host cell behaviors between BEC and LEC and defines the underlying mechanisms of the lymphatic cell environment supporting persistent infection in Kaposi sarcoma tumors. SIGNIFICANCE: This study defines the mechanism by which Kaposi's sarcoma could be maintained by virus constantly produced by lymphatic cells in HIV-positive individuals. ©2020 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32518204 PMCID: PMC7759148 DOI: 10.1158/0008-5472.CAN-19-3105
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701